Evidence analysisOctober 20, 2026Privacy & Data
European Sales and Use of Antimicrobials for Veterinary Medicine (ESUAvet) annual surveillance reports

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
Privacy & Data: European Surveillance of Antimicrobials in Veterinary Medicine
What is established
The European Medicines Agency (EMA) manages a comprehensive surveillance initiative called ESUAvet (European Sales and Use of Antimicrobials for Veterinary Medicine). It collects, analyses, and publishes annual data concerning the sales and use of antimicrobial medicinal products in animals across European Union (EU) and European Economic Area (EEA) countries. The program supports the monitoring of antimicrobial consumption in animals and helps track progress towards prudent use of these medicines, which is critical in fighting antimicrobial resistance.
This effort is aligned with the Veterinary Medicinal Products Regulation and includes systematic data reporting from national competent authorities responsible for veterinary antimicrobial monitoring across multiple EU and EEA member states. Reporting started with sales volumes and has gradually incorporated use data by animal species, covering both food-producing and non-food-producing species.
What the source claims
According to the EMA’s recent update (October 2026), ESUAvet publishes annual surveillance reports based on the data submitted annually by member states. These reports provide indicators of antimicrobial consumption in animals and serve as references for stakeholders including policymakers, veterinarians, scientists, and risk assessors. The first reports were published for 2023 and 2024, with future reports planned annually before the end of each calendar year.
The source details how data are reported through the EMA’s Antimicrobial Sales and Use Platform, notes the gradual timeline for species-specific use reporting to be completed by 2030, and lists the national authorities submitting data. It also describes the ESUAvet network, a collaborative platform facilitating coordination and data sharing between EMA and member states, replacing a previous working group.
What may be missing from the usual framing
The EMA presentation focuses strongly on the technical and collaborative aspects of data collection and reporting but offers limited discussion on privacy concerns relating to the granular data collected or the transparency of data access beyond authorized institutions. The publicly available summary dashboards are designed for visualization rather than direct download, restricting independent, reproducible analysis. Privacy or confidentiality frameworks governing the handling and potential anonymization of data at national or EU levels are not explicitly addressed.
Additionally, potential conflicts of interest or economic pressures influencing national reporting completeness or accuracy are not outlined, despite the importance of reliable data in antimicrobial policy. The source does not elaborate on how data privacy protections intersect with veterinary data reporting or whether farmers and veterinarians have rights or controls over the distributed data linked to their antimicrobial use.
Competing evidence or uncertainty
Evidence is insufficient within this source to evaluate the extent of data privacy protections or transparency mechanisms in detail. It is unclear whether all member states comply equally or whether differences in data quality or completeness exist due to institutional capacity or local regulatory frameworks.
Beyond EMA’s reports, independent audits or third-party evaluations of ESUAvet’s data privacy provisions or reporting robustness are not referenced, leaving open questions about systemic weaknesses or gaps. Also, the balance between public health interests in surveillance and individual or corporate privacy rights remains unaddressed.
Why it matters
The ESUAvet surveillance system is a major component of EU efforts to monitor antimicrobial use in animals, which directly relates to the broader global challenge of antimicrobial resistance (AMR). Reliable consumption data enable evidence-based policymaking aimed at prudent antimicrobial use to reduce resistance risks.
However, the collection of detailed veterinary medicine usage data inherently involves processing potentially sensitive commercial and health-related information. How this data is protected, anonymized, and shared affects the willingness of stakeholders to participate honestly, the risk of misuse, and public trust in the surveillance framework. Transparency about privacy safeguards is key in balancing public health interests with data protection rights.
Given the scale and institutional involvement, ensuring robust privacy standards while maintaining data utility for monitoring purposes is a critical governance challenge with implications for future EU data policies covering animal health and beyond.
What to verify next
- Review official ESUAvet annual surveillance reports and supporting documents for stated data privacy, confidentiality measures, and data access policies.
- Investigate national competent authorities’ data governance frameworks, including any legal instruments protecting veterinary antimicrobial use data.
- Seek independent analyses or audits assessing data quality, privacy protections, and transparency of ESUAvet reporting.
- Explore stakeholder perspectives, including veterinarians, farmers, and privacy advocates, on the handling and publication of antimicrobial use data.
- Monitor developments in EU digital and health data regulations that may impact veterinary data privacy and reporting frameworks.
Readers are encouraged to consult the original EMA source and reports for detailed, up-to-date data and institutional policies before drawing conclusions.
Source & verification
Primary source: What's new · October 19, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…